Kornimate/medical-research-clean huggingface dataset:
effect of potato fiber on appetite and fecal fat excretion

Conditions: Fecal Fat Increased; Obesity; Appetite

Summary: results have indicated that some dietary fibers increase fecal fat excretion and particularly viscous fibers suppress appetite sensation and reduce energy intake. both these effects may contribute to body weight management. aim: the aim of the study is to investigate the potential of 3-weeks daily intake of potato pulp (fiberbind), rhamnogalacturonan i isolated potato fiber (rg-i) vs. a low-fiber control (placebo) on satiety and fecal fat excretion in healthy adults. furthermore, a number of secondary endpoints are investigated.


Eligibility criteria:
inclusion criteria: * healthy men * bmi between 18.5 and 27.0 kg/m2 * age 20-40 years exclusion criteria: * intake of potatoes with main meals more frequent than 4 times per week * chronic diseases (known diabetes, cardiovascular disease, irritable bowels disease, colitis ulcerosa, crohn disease, or other chronic diseases which could affect the results of the present study) * gluten allergy * use of daily prescription medicine (mild analgesics are allowed) * use of lipid-lowering agents (e.g. becel, husk) * use of food supplements of relevance to the study (such as pre- and probiotics) * irregular intake of vitamin /mineral supplements (two weeks prior to and during the entire study period) * smoking * elite athletes (\>10 hours of strenuous physical activity per week) * blood donation (\<1 month before study commencement and during study period) * participation in other clinical studies (\<1 month before study commencement and during study period) * inability (physically or psychologically) to comply with the procedures required by the protocol judged by the investigator
functional mri study of attention in normal controls and traumatic brain injured patients

Conditions: Mild Traumatic Brain Injury

Summary: the purpose of this study will be to assess the attentional ability of patients with mild to moderate traumatic brain injury (tbi) using the functional magnetic resonance imaging (fmri) technique. methodology for specific aim 1: sagittal pilot scan, 3-d anatomical mri, whole brain echo-planar imaging (epi), and functional mri techniques with traumatic brain injured subjects doing a continuous performance test (cpt) attention task and compare the pattern of activation with those of normal controls to see if there is a failure to activate frontal lobes in the traumatic brain injured subjects.


Eligibility criteria:
inclusion criteria: * mild to moderate brain injury patients referred to the uci brain imaging center. * mild brain injury patients will be defined as having a glascow coma scale (gcs) scale of 13-15. * moderate brain injury brain injury patients will be defined as having a glascow coma scale (gcs) scale of 9-12 . * normal healthy control subjects (20) exclusion criteria: * pre-accident neuropathology, psychopathology, or secondary neuropathological complications, or chemical abuse * patients who required intracranial surgical intervention * children, pregnant women, or institutionalized individuals unable to freely give consent * patients with implanted surgical clips (hemostatic clips) or other ferromagnetic material * patients engaged in occupations or activities which may cause accidental lodging of ferromagnetic materials, or who may have imbedded metal fragments from military activities * patients with permanent (tattoo) eye-liner or with facial make-up (severe eye irritation has been reported) * patients with metallic implants, because they may cause artifacts in diagnostic images due to magnetic field distortion * patients with implanted prosthetic heart valves * patients with pacemakers, neuro-stimulation devices * subjects who have severe claustrophobia.

Keywords: mild traumatic brain injury fmri
covid-19 and the healthy minds program for educators

Conditions: Anxiety; Depression; Psychological Stress; Psychological Distress; Well-being

Summary: this study is a randomized controlled trial (rct) of the four-week healthy minds program (hmp) app foundations training in employees of a mid-size urban school district in the united states during the summer of 2020, in the midst of the novel coronavirus pandemic. a 3-month follow-up in the fall of 2020 will also be conducted. participants will be recruited via email and mailed postcards, and will first complete an online screen. eligible participants will then enter a waiting zone for between 2-days and 2-weeks before they are sent the online pre-test. upon completion of the pre-test, participants will be assigned to condition via a simple random number generator. if assigned to the intervention (i.e., the healthy minds program app), participants will receive instructions and support in downloading and activating the app. every 7-days over the 4-week intervention period participants in both conditions will complete the same set of measures. a full battery of measures will be administered a second time post-test, following the 4-week intervention period. three-months after post-test, a follow-up assessment will be conducted. the investigators predict that participants assigned to the intervention will demonstrate significantly reduced psychological distress after the intervention, and these decreases will persist at the 3-month follow-up. further, it is hypothesized that baseline participant characteristics and early experience of the intervention will predict treatment adherence, study drop-out and outcomes, and that treatment engagement will moderate outcomes.


Eligibility criteria:
inclusion criteria: * ages 18 years old and up * employees of a k-12 school district in wisconsin * smartphone or device that can download apps from google play or the itunes app store exclusion criteria: * individuals under 18 years old * significant meditation experience: 1. meditation retreat experience (meditation retreat or yoga/body practice retreat with significant meditation component), 2. regular meditation practice weekly for over 1 year or daily practice within the previous 6 months; or 3. previous use of the hmp app. * patient-reported outcomes measurement information system (promis) depression score \> 70
agonist trigger with hcg luteal supplementation vs hcg trigger with progesterone luteal supplementation in antagonist controlled hyperstimulationcycle

Conditions: Infertility, Female

Summary: the aim of the current study is to compare agonist trigger and hcg luteal support vs standard hcg trigger and progesterone luteal supplementation in antagonist controlled hyperstimulation cycle as regards to clinical pregnancy rate.

prospective interventional randomized pilotstudy on patients undergoing controlled ovarian hyperstimulation. all patients will receive a fixed dose of 150-300 iu recombinant fsh (gonal-f; sereno laboratories,madrid, spain) for ovarian stimulation according to age, bmi and antral follicle count (afc). after 6 days of stimulation, fsh will be adjusted according to ovarian response. premature lh surge will be prevented with 0.25 mg of a gnrh antagonist (cetrotide; serono international, geneva, switzerland) starting on day 6 when two or more follicles reach a size of 18-20 mm, trigger of ovulation will be done and followed by luteal phase support according to the protocol assigned for each group. group 1: a single dose of 0.2 mg triptorelin (decapeptyl® ipsen pharmaceutical company, france) and follow up with daily 125 iu hcg injections group 2: a single dose of hcg 10000 iu was given followed by progesterone supplementation with 100mg im (prontogest®).

Eligibility criteria:
inclusion criteria: * age between 20 and 39 years. * body mass index between 18 and 30. * unexplained infertility or male factor infertility exclusion criteria: * endocrinological disorder eg.:hyperprolactenemia, hypo or hyper thyrodism * more than 2 previous attemptsof ivf * any uterine anatomical anomaly.
the effect of eddy sonic versus af max activation of bio-ceramic sealer on post-operative pain in teeth with symptomatic irreversible pulpitis with apical periodontitis

Conditions: Irreversible Pulpitis with Apical Periodontitis

Summary: the aim of endodontic therapy for an inflamed tooth is to eliminate the source of inflammation. relieving pain depends on the effectiveness of root canal therapy.3 postoperative pain in endodontic treatments, affecting 3-58% of patients, is often caused by peri-radicular tissue injuries. understanding these factors helps professionals select methods and supplies to minimize discomfort. 30 patients will be divided into 3 groups according to the method of activation (10 par ticipants/each). participants will be recruited from the postgrad clinic of the endodontic department faculty of oral and dental medicine, future university in egypt patients with mature mandibular first permanent molar with irreversible pulpitis with apical periodontitis intervention 1: bio-ceramic sealer activation with eddy sonic intervention 2: bio-ceramic sealer activation with af max control/comparator: bio-ceramic sealer without activation the study aims to evaluate the effect of eddy sonic and af max activation of bio-ceramic sealer on postoperative pain in mandibular first molars with symptomatic irreversible pulpitis with apical periodontitis


Eligibility criteria:
inclusion criteria: * age range is from 18 to 40 years old. * no sex predilection * patients seeking root canal treatment. * restorable teeth. * positive patient acceptance for participating in the study. * patients able to sign informed consent. * systematically healthy patient (asa i, il). * patient who can understand the numerical rate scale and sign an informed consent. * mandibular first molar teeth with pain on bite or percussion * preoperative sharp (moderate or severe) pain. * vital response of pulp tissue to cold pulp tester (ethyl chloride spray). * widening in periodontal membrane space in radiographic appearance. exclusion criteria: * patients with american association of anesthesiologists (asa) classifications other than asa 1 \& il * patients who have already ingested preoperative medication, such as analgesics, non-steroidal, or steroidal anti-inflammatory drugs, within 12 hours of the start of treatment. * this was done to prevent any misinterpretation of the diagnosis or post-treatment pain severity, as these drugs substantially lower post-endodontic pain (jorge-arajo et al.,2018). * patients with nsaid allergy. * patients having two or more adjacent teeth needing root canal therapy * pregnant patients. * patients with bleeding disorder. * patients with long-term corticosteroid use. * teeth having: * necrotic pulp. * history or presence of swelling or fistulous tract. * acute/chronic periapical abscess. * mobility more than grade 1. * pocket depth of more than 5mm * no possible restorability. * previous root canal treatment. * periapical radiolucency. * external or internal resorption * vertical root fracture. * tmj problems, bruxism, clenching or traumatic occlusion. * inability to understand and perform the given instructions.
studying biomarkers in samples from patients with recurrent or metastatic head and neck cancer treated on e1302 trial

Conditions: Head and Neck Cancer

Summary: rationale: studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this laboratory study is looking at biomarkers in samples from patients with recurrent or metastatic head and neck cancer treated on ecog-e1302 trial.

objectives: * to evaluate the frequency of atp-binding cassette, sub-family g (white), member 2 (abcg2), met proto-oncogene (hepatocyte growth factor receptor) (c-met), and v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (k-ras) polymorphisms or mutations in this study population and the predictiveness of these polymorphisms on survival, time to progression, response rate, and toxicities. outline: archived tumor tissue and peripheral blood mononuclear cells are analyzed for the frequency of abcg2, c-met, and k-ras polymorphisms or mutations by polymerase chain reaction (pcr). results are then correlated with patients' clinical outcomes and toxicity.

Eligibility criteria:
disease characteristics: * patients diagnosed with recurrent or metastatic head and neck cancer treated on eastern cooperative oncology group (ecog)-e1302 trial * patients treated with docetaxel with versus without gefitinib * existing paraffin blocks and peripheral blood mononuclear cells patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: recurrent squamous cell carcinoma of the hypopharynx stage iv squamous cell carcinoma of the hypopharynx recurrent squamous cell carcinoma of the larynx stage iva squamous cell carcinoma of the larynx stage ivb squamous cell carcinoma of the larynx stage ivc squamous cell carcinoma of the larynx recurrent squamous cell carcinoma of the lip and oral cavity stage iva squamous cell carcinoma of the lip and oral cavity stage ivb squamous cell carcinoma of the lip and oral cavity stage ivc squamous cell carcinoma of the lip and oral cavity recurrent metastatic squamous neck cancer with occult primary recurrent squamous cell carcinoma of the nasopharynx stage iv squamous cell carcinoma of the nasopharynx recurrent squamous cell carcinoma of the oropharynx stage iva squamous cell carcinoma of the oropharynx stage ivb squamous cell carcinoma of the oropharynx stage ivc squamous cell carcinoma of the oropharynx recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity recurrent salivary gland cancer stage iva salivary gland cancer stage ivb salivary gland cancer stage ivc salivary gland cancer
a multi-centre, prospective surveillance to assess mid-term performance of the mpact cup

Conditions: Osteoarthritis; Arthritis; Avascular Necrosis; Fracture of the Femoral Neck or Head; Congenital Hip Dysplasia

Summary: this is a multi-centre, prospective post marketing surveillance study to assess mid-term performance of the mpact cup in subjects requiring primary total hip arthroplasty.


Eligibility criteria:
inclusion criteria: * patients who are willing and able to provide written informed consent for participation in the study. written informed consent must be obtained prior to the patient's surgery. * those presenting with disease that meets the indications for use for medacta usa implants defined by this study (on-label use). * patients must be willing to comply with the pre and post-operative evaluation schedule. exclusion criteria: * those with one or more medical conditions identified as a contraindication defined by the labeling on any medacta implants used in this study.
a study to assess the efficacy and safety of brivaracetam as treatment for increased seizure activity in an epilepsy monitoring unit setting

Conditions: Epilepsy

Summary: the purpose of this study is to assess the efficacy of intravenous brivaracetam (brv) compared to intravenous lorazepam (lzp) in subjects with epilepsy undergoing epilepsy monitoring unit (emu) evaluation who experience seizures that require prompt treatment.


Eligibility criteria:
inclusion criteria: * subject is male or female, 18 to 70 years of age, inclusive * subject has an established diagnosis of epilepsy * subject has been admitted to the institution's epilepsy monitoring unit (emu) for seizure characterization or noninvasive presurgical evaluation or such admission is planned within 21 days of screening exclusion criteria: * subject has previously participated in this study and was treated with study drug. re-screen is permitted * subject has participated in another study of an investigational medicinal product (imp) or a medical device within the previous 30 days of epilepsy monitoring unit (emu) admission or is currently participating in another study of an imp or a medical device * subject has taken brivaracetam (brv) in the 21 days prior to emu admission * history or presence of status epilepticus during the 6 months prior to emu admission * subject has a medical or psychiatric condition that in the opinion of the investigator could jeopardize or would compromise the subject's ability to participate in this study * subject has \> 2x upper limit of normal (uln) of any of the following: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or \> uln total bilirubin * subject has chronic liver disease * subject has hypersensitivity to brv or any of its excipients * subject has a history of alcohol or drug abuse during the 6 months prior to emu admission * subject with a history of psychogenic seizures * subject is a pregnant or lactating female * subject has a history of a significant adverse event (ae) due to a benzodiazepine in the opinion of the investigator * subject has respiratory failure (or is at risk for respiratory failure), untreated sleep apnea, or other severe cardiorespiratory disease with new york heart association class iii or iv functional status, or requires supplemental oxygen * subject has acute narrow-angle glaucoma or myasthenia gravis * subject is receiving benzodiazepine treatment (defined as an average of \>=4 administrations per week) that started less than 28 days prior to emu admission * subject has a known allergic reaction or intolerance to benzodiazepines or benzodiazepine excipients

Keywords: epilepsy brivaracetam epilepsy monitoring unit increased seizure activity
adapting a mammography decision aid to support women living in a community contaminated by pfas

Conditions: Breast Cancer Screening

Summary: this community-engaged research project will test an adapted online breast cancer screening decision aid to address the needs of women living in an area where environmental contamination has increased concern about breast cancer risk. it will provide novel data on individual experiences with breast cancer risk assessment and decisional determinants of screening choices in a community disproportionately impacted by industrial pollution.

environmental contamination is increasingly recognized as a critical driver of cancer disparities, and communities impacted by industrial pollution experience greater risk of cancer and higher cancer worry which complicates health decision making. recently the national academies of science engineering and medicine (nasem) released guidance suggesting that per- and polyfluoroalkyl substances (pfas) are suggestively associated with breast cancer risk and that individuals with moderate to high blood concentrations of these chemicals should screen for breast cancer according to age and other risk factors as recommended by the us preventive services task force (uspstf). mammography screening guidelines for women in their 40s increasingly call for the use of risk assessment tools to guide screening initiation and imaging intervals (e.g. every year vs. every two years), but current tools do not address environmental risk factors that can contribute to breast cancer risk. this poses a particular challenge in communities where there is a real or perceived increased risk of breast cancer stemming from an environmental contamination concern. there are currently no decision tools tailored to help women living in such communities with their decisions about breast cancer screening. therefore, the goal of the proposed work is to test an adapted online decision aid to incorporate environmental risk messaging to increase informed breast cancer screening decisions for women 40-49 years of age living in the greater merrimack, new hampshire area, where known and ongoing pfas contamination exists. in partnership with merrimack citizens for clean water, we will distribute a community survey among screening-eligible women to test the new risk messaging within the decision aid (n=100) and establish acceptability in an open-label, single arm trial. the proposed research will contribute novel data on community-driven priorities for information about environmental contaminants that may affect breast cancer risk assessment and screening decisions.

Eligibility criteria:
inclusion criteria: * females aged 39-49 * no personal history of breast cancer, * no mammogram in the prior 12 months * resident of merrimack, hillsborough, rockingham or bennington counties exclusion criteria: * history of breast cancer, ductal carcinoma in situ, lobular carcinoma in situ * cognitive impairment impeding the ability to provide informed consent

Keywords: per- and polyfluoroalkyl substances breast cancer screening decision aid risk assessment
lay user evaluation of the panbio™ hcv self test in an eu population

Conditions: Hepatitis C

Summary: this study is part of the performance evaluation to support the conformity assessment procedure for the use of fingerstick whole blood samples with abbott's panbio™ hcv self test device, as performed by lay users. the study will be conducted in accordance with the commission implementing regulation (eu) 2022/1107 of 4 july 2022 laying down common specifications for certain class d in vitro diagnostic medical devices in accordance with regulation (eu) 2017/746 of the european parliament and of the council and, to provide data to demonstrate the product is safe and effective for its intended use.

hepatitis c is a liver disease caused by the hepatitis c virus (hcv). the virus can cause both acute and chronic disease, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. globally, around 50 million people per year are living with hcv, resulting in 244,000 deaths. the who estimates that only 36% of individuals chronically infected with hcv are diagnosed, and the who hcv targets include increasing the diagnoses to 90% by 2030. who guidelines, published in 2021, strongly recommend offering self-testing for hcv as an additional approach to hcv testing services. the panbio™ hcv self test, is a lateral flow test, designed for the qualitative detection of antibodies specific to hcv in finger-stick whole blood. the test is designed to be used by lay users and uses a sample volume of 10 µl. the professional use version test (bioline™ hcv test) is commercially available and has previously been clinically validated by the manufacturer, demonstrating a sensitivity of 99.3-100% and a specificity of 98.1-100%. evaluation of the test performance when used by professional users has been conducted, and evaluation of lay user sensitivity and specificity based on lay user populations outside the eu is being conducted. this study will demonstrate the test performance and usability of the test when used in a european lay user population. the study will be conducted at one recruiting hospital in spain.

Eligibility criteria:
inclusion criteria: * participant is aged 18 or over * participant agrees to all aspects of the study and is able and willing to provide informed consent / assent with parental consent. exclusion criteria: * participant has already participated in this study on a previous occasion. * participant is deemed unfit for the study by the investigator. * participant has a condition deemed unfit by the investigator to safely perform or receive the test. * participant is a practising health-care professional or laboratory scientist / technician or has prior medical or laboratory training or experience * participant is currently enrolled in a study to evaluate an investigational drug or vaccine. * participant has a visual impairment that cannot be restored using glasses or contact lenses or is unable to read the instructions for use. * participant is unwilling or unable to provide informed consent.

Keywords: rapid diagnostic test antibodies to hepatitis c virus (hcv). self-test lay user